- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07285239
Belantamab Mafodotin o Daratumumab con Bortezomib, Lenalidomide e Desametasone per il Mieloma Multiplo di Nuova Diagnosi (PrE1005)
Studio randomizzato di Fase 3 con Belantamab Mafodotin o Daratumumab in combinazione con Bortezomib, Lenalidomide e Desametasone per il Mieloma Multiplo di nuova diagnosi
Eligible participants with newly diagnosed myeloma who are not considered eligible or refuse bone marrow transplant will be enrolled. Participants will be randomized to either belantamab mafodotin or daratumumab given in combination with bortezomib, lenalidomide and dexamethasone. Treatment will continue until disease progression, unacceptable side effects or withdrawal of consent.
Belantamab mafodotin is a targeted cancer treatment that works against multiple myeloma cells. It combines a homing device (an antibody) with a powerful cell-killing drug (a toxin), delivering the toxin directly to cancer cells while largely sparing healthy cells.
Minimal residual disease (MRD) testing will be done on bone marrow samples obtained standardly during your treatment. MRD shows whether a very small number of cancer cells can still be detected after treatment, even if standard lab tests shows no signs of cancer.
The purpose of this study is to evaluate if belantamab mafodotin, bortezomib, lenalidomide and dexamethasone (BVRd) improves minimal residual disease (MRD) negative status and/or prolongs progression-free survival (PFS) compared with daratumumab, bortezomib, lenalidomide and dexamethasone (DVRd) in participants with newly diagnosed multiple myeloma.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This proposed Phase III multicenter, study is a randomized (1:1), open-label trial designed to show belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone (VRd) will lead to higher minimal residual disease (MRD) negativity rate compared with daratumumab in combination with VRd newly diagnosed multiple myeloma (TI-NDMM). Patients must be ineligible for autologous stem cell transplantation because of their age (≥ 70 years) or aged 18 - 70 years with the presence of underlying medical conditions likely to have a negative impact on tolerability of high-dose chemotherapy with stem-cell transplantation, making them transplant ineligible OR transplant-eligible and refusing stem-cell transplantation until first relapse or later. In addition, progression-free survival (PFS) will also be longer.
After enrolling approximately 320 standard-risk patients (anticipated at approximately 400 total patients), the study will limit accrual to patients with high risk NDMM to allow for enrichment of this subgroup of patients.
Belantamab mafodotin is a monoclonal antibody that targets B-cell maturation antigen (BCMA), a protein expressed on the surface of plasma cells, and releases a cytotoxic agent called Monomethyl auristatin F, which destroys the plasma cells.
International Myeloma Working Group (IMWG) criteria will be used for disease response.
MRD samples will be obtained on standard of care bone marrow procedures. MRD testing will be performed on samples at time of screening, suspected complete response (sCR), after confirmed CR at applicable time points from Cycle1, Day 1 at 6, 12, 18 (optional), 24, 30 (optional) and 36 months then annually until progression. MRD testing will not be performed in real-time for this study. Bone marrow samples will also be obtained for future research at screening and time of progression.
Research peripheral blood samples will be obtained to measure levels of belantamab mafodotin in the blood, immune responses or antibodies to belantamab mafodotin for patients receiving belantamab mafodotin. In addition, research blood samples will be obtained on all patients to measure soluble B-cell maturation antigen (sBCMA) to help diagnose, monitor treatment effectiveness, and predict the prognosis of multiple myeloma.
Patient-reported outcomes will also be performed.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 3
Contatti e Sedi
Contatto studio
- Nome: Michael Wright, MS
- Numero di telefono: 267-319-3910
- Email: PrE1005@precogllc.org
Luoghi di studio
-
-
Iowa
-
Des Moines, Iowa, Stati Uniti, 50309
- Reclutamento
- Iowa Oncology Research Associates
-
Contatto:
- Tracy Sarin
- Numero di telefono: 515-241-3305
- Email: tsarin@iora.org
-
Investigatore principale:
- Millicent Amankwah, MD
-
-
Maine
-
Brewer, Maine, Stati Uniti, 04412
- Reclutamento
- Northern Lights / Eastern Maine Medical Center
-
Contatto:
- Laurie Lewis
- Numero di telefono: 207-973-4249
- Email: llewis@northernlight.org
-
Investigatore principale:
- Sarah Sinclair, DO
-
-
Wisconsin
-
La Crosse, Wisconsin, Stati Uniti, 54601
- Reclutamento
- Gundersen Lutheran
-
Contatto:
- Tory Borzyskowski
- Numero di telefono: 608-775-8521
- Email: tori.borzyskowski@emplifyhealth.org
-
Contatto:
- Savannah Shallue
- Numero di telefono: 608-775-4113
- Email: savannah.shallue@emplifyhealth.org
-
Investigatore principale:
- Yacki Hayashi-Tanner, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Eligibility Criteria:
-
Patient must have suspected or confirmed newly diagnosed multiple myeloma (MM) by International Myeloma Working Group (IMWG) criteria and must not have received more than one cycle of any myeloma treatment.
-
Patient must be considered ineligible for autologous stem cell transplantation by the treating physician because of their age (≥ 70 years) or aged 18 - 70 years with the presence of underlying medical conditions likely to have a negative impact on tolerability of high-dose chemotherapy with stem-cell transplantation, making them transplant ineligible, OR transplant-eligible and refusing stem-cell transplantation until first relapse or later.
-
Patient must have measurable or evaluable disease as defined by having one or more of the following, obtained within 28 days prior to randomization.
- ≥ 1g/dL monoclonal protein (M-protein) on serum protein electrophoresis
- Involved free light chain ≥ 10 mg/dL or ≥ 100 mg/L AND abnormal serum immunoglobulin kappa to lambda free light chain ratio (<0.26 or >1.65)
- ≥ 200 mg/24 hours of monoclonal protein on a 24-hour urine protein electrophoresis
- Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)
-
Patient must be ≥ 18 years and <80 years of age.
-
Patient must have an Eastern Cooperative Group (ECOG) Performance Status (PS) of 0-2 (PS 3 allowed if secondary to pain).
-
Patient must have IMWG Frailty Score <2.
-
Patient must have the ability to understand and willingness to sign a written informed consent document.
-
Patient must be willing to provide bone marrow (aspirate and/or biopsy) and blood samples for determination of International Myeloma Society (IMS) risk status and for research. Indeterminate patients with missing or unevaluable samples will be excluded.
-
Patient must have received no more than one cycle (28 days or less) of prior chemotherapy and no more than 160 mg of prior dexamethasone (or equivalent dose of prednisone) for treatment of symptomatic myeloma. Prior radiation therapy to symptomatic lesions is allowed provided there is no residual toxicity related to radiation and blood counts meet the study requirements. NOTE: Patients who have received prior treatment for smoldering multiple myeloma (SMM) are eligible.
-
Patient must have a Serum Protein Electrophoresis (SPEP), Urine Protein Electrophoresis (UPEP), and serum Free Light Chain (FLC) assay performed within 28 days prior to registration. In addition, a bone marrow biopsy and/or aspirate is required within 28 days prior to registration if measurable disease is only present in bone marrow. Otherwise, a bone marrow examination must have been performed within 90 days prior to registration.
-
Patient must have adequate organ function and marrow function as defined below, obtained ≤ 2 weeks prior to registration.
- Absolute Neutrophil Count (ANC) ≥ 1000/microliter (mcL)
- Platelets ˃75,000/mcL
- Creatinine clearance (CrCl) ≥ 30 mL/min
- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 3x upper limit of normal (ULN)
- Total Bilirubin ≤ 1.5x ULN or ≤ 3x ULN for patients with documented Gilbert's disease
-
Patient must agree to register to the mandatory lenalidomide (Revlimid) Risk Evaluation and Mitigation Strategy (REMS) program and be willing and able to comply with the requirements of the REMS program.
-
Patient must not be pregnant or breast-feeding due to the potential harm and teratogenic effects to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
-
Patient must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study, and for 3 months after the last dose of protocol treatment.
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial.
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
-
Patient with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association (NYHA) Functional Classification. To be eligible for this trial, patient must be class 2 or better.
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
-
Patients must not have peripheral neuropathy ≥ Grade 2 on clinical examination or Grade 1 with pain at time of registration.
-
Patients must not have any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with the completion of treatment according to this protocol.
-
Patient may have a history of current or previous deep vein thrombosis (DVT) or pulmonary embolism (PE) but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation.
-
Patients must not have any known allergies, hypersensitivity, or intolerance to corticosteroids, monoclonal antibodies or human proteins, or their excipients, or known sensitivity to mammalian-derived products.
-
Patients must not have current corneal epithelial disease except mild punctuate keratopathy.
-
Contact lenses must be avoided for participants while they are receiving belantamab mafodotin treatment unless cleared by an eye-care specialist. If cleared for use, bandaged contact lenses are specifically recommended. Contact lens use may be restarted after discontinuation of belantamab mafodotin treatment, provided the eye-care specialist confirms there are no other contraindications.
-
Patients must not have symptomatic amyloidosis or active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma-proliferative disorder, skin changes) at the time of screening.
-
Patients must not receive any other concurrent chemotherapy, or any ancillary therapy considered investigational while on this protocol.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm A: Belantamab Mafodotin
Belantamab mafodotin in combination with bortezomib, lenalidomide and dexamethasone (VRd) until progression, unacceptable toxicity or participant withdrawal. 1 cycle = 28 days. |
1.9 milligram/kilogram (mg/kg) intravenous (IV) will be administered every 8 weeks for first 24 weeks (Cycles 1-3), then 1.9 mg/kg every 12 weeks (Cycles 4+) until progression, unacceptable toxicity or participant withdrawal
Altri nomi:
1.3 milligrams per square meter (mg /m²) SC on days 1, 8 and 15 of every 28 day bortezomib treatment cycle for 8 cycles
Altri nomi:
25 mg orally (PO) Days 1-21 of every 28 day lenalidomide treatment cycle.
Altri nomi:
40 mg PO on Days 1, 8, 15, and 22 of each 28-day cycle (may decrease to 20 mg if >75 years old)
Altri nomi:
|
|
Comparatore attivo: Arm B:
Daratumumab in combination with bortezomib, lenalidomide and dexamethasone (VRd) until progression, unacceptable toxicity or participant withdrawal. 1 cycle = 28 days. |
1.3 milligrams per square meter (mg /m²) SC on days 1, 8 and 15 of every 28 day bortezomib treatment cycle for 8 cycles
Altri nomi:
25 mg orally (PO) Days 1-21 of every 28 day lenalidomide treatment cycle.
Altri nomi:
40 mg PO on Days 1, 8, 15, and 22 of each 28-day cycle (may decrease to 20 mg if >75 years old)
Altri nomi:
1800 mg subcutaneous (SC) will be administered weekly from Week 1-8 (Cycles 1 and 2), every 2 weeks from Week 9-24 (Cycles 3-6), and every 4 weeks from Week 25 (Cycles 7+) onwards until progression, unacceptable toxicity or participant withdrawal
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
MRD Negative Status
Lasso di tempo: Up to 86 months
|
MRD negative status, defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS at least once during the time of confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC); MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result |
Up to 86 months
|
|
Progression-Free Survival (PFS)
Lasso di tempo: Up to 86 months
|
PFS, defined as the time from the date of randomization to the date of first documented disease progression per IMWG criteria by IRC or death from any cause in the absence of progression, whichever occurs first |
Up to 86 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall Survival (OS)
Lasso di tempo: Up to 86 months
|
OS, defined as the time from the date of randomization until the date of death due to any cause |
Up to 86 months
|
|
Best Response of Complete Response (CR)
Lasso di tempo: Up to 86 months
|
Defined as confirmed CR or better per IMWG criteria by IRC |
Up to 86 months
|
|
Best Response of Very Good Partial Response (VGPR)
Lasso di tempo: Up to 86 months
|
Defined as confirmed VGPR, CR or better per IMWG criteria by IRC |
Up to 86 months
|
|
Overall Response Rate (ORR)
Lasso di tempo: Up to 86 months
|
Defined as confirmed PR, VGPR, CR or better per IMWG criteria by IRC |
Up to 86 months
|
|
Duration of Response (DoR)
Lasso di tempo: Up to 86 months
|
DoR, defined as the time from first documented evidence of partial response (PR) or better until progression (PD) or death due to PD (among participants who achieve confirmed PR or better) by IRC |
Up to 86 months
|
|
MRD Negative Status at 12-Month
Lasso di tempo: Up to 86 months
|
Defined as achieving MRD negativity at 10-5 sensitivity threshold assessed by NGS in participants achieving confirmed CR or better response per IMWG criteria by Independent Review Committee (IRC) after 12 (+/-3) months; MRD negativity is determined by the Adaptive Biotechnologies clonoSEQ® assay result |
Up to 86 months
|
|
Sustained MRD (sMRD) Negative Status
Lasso di tempo: Up to 86 months
|
sMRD, defined as achieving MRD negative status at 10-5 sensitivity threshold assessed by NGS at least twice, a minimum of 1 year apart and with no MRD positive result in between, during the time of confirmed CR or better response per IMWG criteria by IRC |
Up to 86 months
|
|
Adverse Events (AEs)
Lasso di tempo: While on study treatment and up to 70 days after the last dose of study medication
|
Worst Grade 3 or Higher Treatment-Related Non-Hematologic and Overall Toxicity based on CTCAE v6.0 |
While on study treatment and up to 70 days after the last dose of study medication
|
|
AEs Leading to Dose Modifications
Lasso di tempo: While on study treatment and up to 70 days after the last dose of study medication
|
AEs or Grade ≥ 2 Corneal Events Leading to Dose Modifications or Treatment Discontinuation |
While on study treatment and up to 70 days after the last dose of study medication
|
|
Corneal Events
Lasso di tempo: While on study treatment and up to 70 days after the last dose of study medication
|
Incidence of Grade ≥ 3 Corneal Events (Keratopathy Visual Acuity (KVA) scale) |
While on study treatment and up to 70 days after the last dose of study medication
|
|
Patient-Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Lasso di tempo: Up to 86 months
|
Frequency and Score of Selected PRO-CTCAE Attributes |
Up to 86 months
|
|
Health-Related Quality of Life (HRQoL)
Lasso di tempo: Up to 86 months
|
Change from Baseline in HRQoL as Measured by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), European Organisation for Research and Treatment of Cancer Quality of Life Multiple Myeloma Questionnaire (EORTC QLQ-MY20), and Functional Assessment of Cancer Therapy - Multiple Myeloma (FACT MM) Subscale |
Up to 86 months
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Cattedra di studio: Shaji Kumar, MD, Mayo Clinic
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Neoplasie, plasmacellule
- Disturbi emostatici
- Paraproteinemie
- Disturbi delle proteine del sangue
- Disturbi emorragici
- Malattie emiche e linfatiche
- Mieloma multiplo
- Composti di zolfo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Idrocarburi, ciclici
- Acidi carbossilici
- Idrocarburi, aromatici
- Composti policiclici
- Piperidine
- Prodotti chimici inorganici
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Derivati di benzene
- Acidi solfonici
- Acidi zolfo
- Incintadienetrioli
- Acidi boronic
- Acidi, non carbossilici
- Acidi
- Composti di boro
- Pirazine
- Ftalimides
- Acidi ftalici
- Acidi, carbociclico
- Piperidoni
- Isoindoli
- Benzenesolfonati
- Arilsulfonati
- Acidi arilsolfonici
- Lenalidomide
- Bortezomib
- Desametasone
- Dobesilato di calcio
- mafodotina di betantamab
Altri numeri di identificazione dello studio
- PrE1005
- GSK 300057 (Altro identificatore: GlaxoSmithKline)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Data is proprietary
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .